James
James @gxp11 ·
Leave your wife. S3xu@lly harass male interns. Siphon money from TPUSA. Reject the uniparty.
Tyler Bowyer Tyler Bowyer @tylerbowyer ·
Keep MAGA together. Give MAHA the due love and attention. Get out of Iran fast. Reject the uniparty. Inject positivity into the movement.
1
Official_Only1hope
Official_Only1hope @HopeIgbo1 ·
“Lagos people are too soft and civilized, that’s why Agberos can b¥lly them. That kind of thing can not happen in Warri and Delta”- Man says
1
3
StockChaser
StockChaser @StockChaser_ ·
It was very clear Since this post, $LLY has dropped ~11%, while $NVO is down ~5% Both are now at very important support levels, but I believe $NVO offers a better risk/reward at these levels If $LLY loses the 50 WMA, I expect a move toward the 200 WMA around $662
StockChaser StockChaser @StockChaser_ ·
Only looking at the charts, guess which one will start a corrective move and which one will likely move higher: $LLY or $NVO? I already know my answer Not financial advice
506
.
. @Wembytradess ·
I plan to add more into MSFT this week if given chance. LLY is a little longer focus that I think can push new highs. but msft is a shorter term position for the next ~2 weeks
3
Bioinvestor24
Bioinvestor24 @bioinvestor24 ·
That’s good take on the trial below To add $LLy tirzepatide addition to IL17 ab markedly improved skin psoriasis clearance .. example PASI90 was achieved in 35% of IL17 ab vs 52% of IL17 plus TZP. This is remarkable improvement, and if TZP were an I&I dedicated biologic , it would have been touted as highly effective addition to IL17 Vomit rate was low at 11% … There was double treatment DC rate in IL17 alone arm vs both ( open label trial ). So pts were not happy they were not on TZP .. $ABBV watching all that .. even CMO alluded to it this month. And even $NVO that wants to add from obesity related conditions. $MRK CMO praised and highlighted this trial at JPM Great news for psoriasis pts ( about 80 % over wt or obese )
Jen Can NuSH Jen Can NuSH @JCanNuSH ·
Full paper is out for Lilly‘s Taltz + Zepbound trial (TOGETHER-PsA) in psoriatic arthritis. $LLY Very cool to see a meaningful improvement in response when these two meds are used together. (Working to get one of my parents to try this combo!) ▪️64% more patients receiving tirzepatide with Taltz hit a 50% reduction in PsA symptoms. ▪️69.7% (vs 10.5% on Taltz alone) of patients receiving both therapies list at least 5% body weight and had at least a 20% reduction in PsA symptoms. It was also cool that this trial used a max tolerated dose for tirzepatide strategy and went as low as 5mg on that (often they set 10mg as a minimum end dose). For those receiving tirzepatide (and not placebo) with their Taltz, 78.9% of participants with reported dosing data had TZP 15 mg, 8.3% TZP 10 mg, and 9.2% TZP 5 mg as their MTD. acrjournals.onlinelibrary.wiley.com/doi/10.1002/ar… H/T @DanielJDrucker
1
705
Charan
Charan @_charan_04 ·
$LLY approaching 860 PT
Charan Charan @_charan_04 ·
$LLY inverted cup and handle breakdown - Missed the downside move today - Next PT 915-930 - if that is lost , next is 866
116
Zam
Zam @Zam1140409 ·
Replying to @ZoomerSaxon
@ZoomerSaxon @dpaudits "I don't want white girls to be sexu@lly assaulted by migrants." Unlike me who just doesn't want anyone to be assaulted no matter where they are from Bit weird that migrant abuse is more important to you
1
26
Mr Jim The Trader
Mr Jim The Trader @Philip97285391 ·
$LLY is priced for perfection, but it just might be perfection: New partnership with $NVDA to build lab infrastructure running on the NVIDIA BioNeMo platform and the flagship Vera Rubin accelerator. Part of the partnership is pioneering robotics and physical AI to accelerate AI.
28
Eliyahu Ben Beryl
Eliyahu Ben Beryl @tonythearena ·
Replying to @bioinvestor24
@bioinvestor24 LLY needs to quickly buy a lot of asset with that over valued stock. Seem he big major Pharm never learn! When stock has high value start telling the pipeline with the currency
31
Clinical Trial Alerts
Clinical Trial Alerts @NCTAlerts ·
EU authorization for palbociclib + exemestane in metastatic cancer. $LLY. Phase 3, N=193. #2025-522791-92-00
7